{
    "id": 11629,
    "fullName": "BRD4 - NUTM1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "BRD4-NUTM1 (BRD4-NUT) results from the fusion of BRD4 and NUTM1, and leads to inhibition of cell differentiation (PMID: 17934517, PMID: 21652721). BRD4-NUTM1 fusions are associated with NUT midline carcinoma (PMID: 18552174).",
            "references": [
                {
                    "id": 3614,
                    "pubMedId": 17934517,
                    "title": "BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17934517"
                },
                {
                    "id": 10248,
                    "pubMedId": 21652721,
                    "title": "Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21652721"
                },
                {
                    "id": 10247,
                    "pubMedId": 18552174,
                    "title": "Demystified molecular pathology of NUT midline carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18552174"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 23476,
        "geneSymbol": "BRD4",
        "terms": [
            "BRD4",
            "CAP",
            "HUNK1",
            "HUNKI",
            "MCAP"
        ]
    },
    "variant": "BRD4 - NUTM1",
    "createDate": "09/09/2015",
    "updateDate": "11/06/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 256646,
                "geneSymbol": "NUTM1",
                "terms": [
                    "NUTM1",
                    "C15orf55",
                    "FAM22H",
                    "NUT"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 3116,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Farydak (panobinostat) inhibited tumor growth, increased histone acetylation and induced squamous differentiation of human cancer cells harboring BRD4-NUTM1 in cell line xenograft models (PMID: 21447744).",
            "molecularProfile": {
                "id": 11680,
                "profileName": "BRD4 - NUTM1"
            },
            "therapy": {
                "id": 1080,
                "therapyName": "Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 60463,
                "name": "NUT midline carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3616,
                    "pubMedId": 21447744,
                    "title": "Differentiation of NUT midline carcinoma by epigenomic reprogramming.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21447744"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9920,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 inhibited MYC expression and growth of a NUT midline carcinoma cell line harboring BRD4-NUTM1 in culture, and decreased tumor growth and improved survival in xenograft models (PMID: 27980108).",
            "molecularProfile": {
                "id": 11680,
                "profileName": "BRD4 - NUTM1"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 60463,
                "name": "NUT midline carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7758,
                    "pubMedId": 27980108,
                    "title": "Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27980108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3115,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zolinza (vorinostat) increased histone acetylation, induced growth arrest and squamous differentiation in human cancer cells harboring BRD4-NUTM1 in culture (PMID: 21447744).",
            "molecularProfile": {
                "id": 11680,
                "profileName": "BRD4 - NUTM1"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3616,
                    "pubMedId": 21447744,
                    "title": "Differentiation of NUT midline carcinoma by epigenomic reprogramming.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21447744"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3114,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, trichostatin A increased histone acetylation, induced growth arrest and squamous differentiation in human cancer cells harboring BRD4-NUTM1 in culture (PMID: 21447744).",
            "molecularProfile": {
                "id": 11680,
                "profileName": "BRD4 - NUTM1"
            },
            "therapy": {
                "id": 2867,
                "therapyName": "Trichostatin A",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3616,
                    "pubMedId": 21447744,
                    "title": "Differentiation of NUT midline carcinoma by epigenomic reprogramming.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21447744"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7182,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, TEN-010 treatment given at 0.45 mg/kg resulted in tumor regression in two NUT midline carcinoma patients harboring BRD4-NUTM1 fusion (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A49).",
            "molecularProfile": {
                "id": 11680,
                "profileName": "BRD4 - NUTM1"
            },
            "therapy": {
                "id": 937,
                "therapyName": "TEN-010",
                "synonyms": null
            },
            "indication": {
                "id": 60463,
                "name": "NUT midline carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6144,
                    "pubMedId": null,
                    "title": "Clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC)",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/A49"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6007,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Birabresib (OTX015) treatment resulted in clinical and radiologic partial responses in two patients, stable disease with alleviation of symptoms within the first two weeks of therapy initiation in one patient, and rapid disease progression in one patient with BRD4-NUTM1 positive NUT midline carcinoma (PMID: 26976114).",
            "molecularProfile": {
                "id": 11680,
                "profileName": "BRD4 - NUTM1"
            },
            "therapy": {
                "id": 2034,
                "therapyName": "Birabresib",
                "synonyms": null
            },
            "indication": {
                "id": 60463,
                "name": "NUT midline carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5226,
                    "pubMedId": 26976114,
                    "title": "Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26976114"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3610,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Istodax (romidepsin) demonstrated limited efficacy, as a monotherapy, in 14 patients with head and neck squamous cell carcinoma (PMID: 22748449).",
            "molecularProfile": {
                "id": 11680,
                "profileName": "BRD4 - NUTM1"
            },
            "therapy": {
                "id": 1075,
                "therapyName": "Romidepsin",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3882,
                    "pubMedId": 22748449,
                    "title": "Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22748449"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3113,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQ1 inhibited proliferation and induced differentiation of a NUT midline carcinoma cell line harboring BRD4-NUTM1 in culture (PMID: 20871596).",
            "molecularProfile": {
                "id": 11680,
                "profileName": "BRD4 - NUTM1"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 60463,
                "name": "NUT midline carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3615,
                    "pubMedId": 20871596,
                    "title": "Selective inhibition of BET bromodomains.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20871596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11680,
            "profileName": "BRD4 - NUTM1",
            "profileTreatmentApproaches": [
                {
                    "id": 6454,
                    "name": "BET  Inhibitor (Pan)",
                    "profileName": "BRD4 - NUTM1"
                },
                {
                    "id": 6453,
                    "name": "HDAC Inhibitor",
                    "profileName": "BRD4 - NUTM1"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}